In a recent announcement, Medtronic plc, a global leader in healthcare technology, revealed the FDA approval of its Simplera™ continuous glucose monitor (CGM). This innovative CGM is the company's first disposable, all-in-one device that is half the size of previous Medtronic CGMs. With a discreet design and easy insertion, Simplera™ CGM eliminates the need for overtape, providing a simpler and more comfortable experience for users.

The Simplera™ CGM is part of a comprehensive platform that includes the Simplera Sync™ sensor and the InPen™ smart insulin pen, designed to be used as a Smart MDI system. Earlier this year, the Simplera™ CGM and Simplera Sync™ sensor received CE Mark approval in Europe, with positive feedback received on their ease of use and insertion. These devices complement the highly satisfactory MiniMed™ 780G system, further enhancing Medtronic's diabetes management offerings.

Following FDA clearance, Medtronic plans to initiate a limited market release of Simplera™ CGM in the United States for existing standalone CGM and InPen™ customers. The company is also working on an updated InPen™ smart insulin pen app, which will facilitate integration with Simplera™ CGM as part of a Smart MDI system. Meanwhile, the Simplera Sync™ sensor is currently under review by the FDA and is not yet approved for commercial use in the U.S.

In addition to these advancements, Medtronic announced a global partnership with Abbott to expand continuous glucose monitoring options for individuals living with diabetes. Under this collaboration, the companies will develop an integrated CGM based on Abbott's advanced technology platform. The exclusive CGM will work in conjunction with Medtronic's smart dosing devices and software, supporting both automated insulin delivery and Smart MDI systems. Medtronic expects this partnership to positively impact its Diabetes revenue without affecting the Diabetes gross margin.

Que Dallara, the executive vice president and president of Medtronic Diabetes, expressed excitement about the partnership, stating that it will provide more choice for individuals living with diabetes and create a seamless Medtronic experience. Jared Watkin, the executive vice president of Abbott's diabetes care business, highlighted the combination of two global leaders in glucose sensing technology and insulin delivery, emphasizing how the integration of Abbott's CGM with Medtronic's advanced insulin delivery systems will enable users to focus more on living life and less on managing their diabetes.

Medtronic is committed to advancing its pipeline to meet the needs of people requiring intensive insulin delivery, including developing next-generation durable and patch automated insulin delivery systems, smart pens, CGMs, algorithms, software, and services. The company aims to expand therapy indications and continue improving the lives of individuals with diabetes.

About Medtronic:
Medtronic plc, headquartered in Dublin, Ireland, is a leading global healthcare technology company dedicated to finding solutions for the most challenging health problems. With a global team of over 95,000 passionate individuals spread across 150 countries, Medtronic develops and delivers innovative technologies and therapies to treat 70 different health conditions. Their range of products includes cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and much more.

Disclaimer: The article contains forward-looking statements and reflects the information and statements provided by Medtronic. Actual results may vary, and readers are advised to refer to Medtronic's official reports and filings for accurate and updated information on the subject matter.